Shanghai Miracogen Signs a Non-Exclusive License Agreement with Synaffix for its ADC Technologies

 Shanghai Miracogen Signs a Non-Exclusive License Agreement with Synaffix for its ADC Technologies

Shanghai Miracogen Signs a Non-Exclusive License Agreement with Synaffix for its ADC Technologies

Shots:

  • Synaffix to receive upfront and milestones leading to total deal value $125M and royalties on sales of product. Miracogen to get non-exclusive license rights for Synaffix’s GlycoConnect and HydraSpace ADC technologies to develop ADC therapies
  • Miracogen to take care of research, development and commercialization of the developed ADC products and Synaffix to take care of components required for the technology
  • Synaffix’s GlycoConnect and HydraSpace technologies, are an extension to toxSYN technology which produces ADC therapies using Abs. Antibody Drug Conjugate (ADCs) are a targeted mAb carrying a cytotoxic agent

Click here to read full press release/ article | Ref: Synaffix | Image: PharmaWorld

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post